Got story updates? Submit your updates here. ›
A close-up view of the complex financial machinery powering the biotech industry, as institutional investors adjust their positions in leading companies like Amgen.Thousand Oaks TodayOFI Invest Asset Management, a financial services firm, grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 113.0% in the 4th quarter, according to a recent SEC filing. The firm now owns 9,913 shares of the medical research company’s stock, valued at $3.245 million.
Why it matters
Amgen is a major player in the biotechnology industry, developing and manufacturing important therapeutic drugs. Institutional investors closely monitor and adjust their positions in companies like Amgen, as changes in ownership can signal broader market trends or shifts in investor sentiment.
The details
According to the filing, OFI Invest Asset Management added 5,259 shares of Amgen to its portfolio during the fourth quarter of 2025. This significant increase in the firm’s position suggests it sees growth potential in Amgen’s business and stock performance. The filing also noted that several other institutional investors, including West Family Investments Inc., Viawealth LLC, and LOM Asset Management Ltd., hold positions in Amgen.
- OFI Invest Asset Management filed its 13F report for the 4th quarter of 2025 on April 10, 2026.
- The firm increased its Amgen stake during the 4th quarter of 2025.
The players
OFI Invest Asset Management
A global financial services firm that manages investments and assets for institutional and individual clients.
Amgen Inc.
A leading biotechnology company that develops and manufactures innovative human therapeutics to address serious illnesses.
What’s next
Investors will likely continue to monitor Amgen’s stock performance and any further changes in institutional ownership, as these can provide insights into the company’s future growth prospects.
The takeaway
The significant increase in OFI Invest Asset Management’s Amgen position suggests the firm sees strong potential in the biotech company’s pipeline and future growth. This move highlights the importance of closely following changes in institutional ownership for insights into market sentiment around key industry players.
Leave a comment